Loading…

Evaluation of the diagnostic performance of an oral fluid screening test device for substance abuse at traffic controls

The aim of this study was to evaluate the analytical performance of the Kite Biotechnology Oral fluid (OF) screening test device, which is used for roadside screening of cannabis, opiates, amphetamines, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), cocaine and benzodiazepines by compari...

Full description

Saved in:
Bibliographic Details
Published in:Clinical biochemistry 2021-07, Vol.93, p.112-118
Main Authors: Avcioglu, Gamze, Yilmaz, Gulsen, Yalcin Sahiner, Safak, Kozaci, L. Didem, Bal, Ceylan, Yilmaz, Fatma Meric
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c377t-c2715de20722ccd68a88a081656187d8c383a58148dbc2be129a2909e22daee43
cites cdi_FETCH-LOGICAL-c377t-c2715de20722ccd68a88a081656187d8c383a58148dbc2be129a2909e22daee43
container_end_page 118
container_issue
container_start_page 112
container_title Clinical biochemistry
container_volume 93
creator Avcioglu, Gamze
Yilmaz, Gulsen
Yalcin Sahiner, Safak
Kozaci, L. Didem
Bal, Ceylan
Yilmaz, Fatma Meric
description The aim of this study was to evaluate the analytical performance of the Kite Biotechnology Oral fluid (OF) screening test device, which is used for roadside screening of cannabis, opiates, amphetamines, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), cocaine and benzodiazepines by comparing samples with matched plasma samples, analysed via liquid chromatography–tandem mass spectrometry (LC-MS/MS) for confirmation. OF and plasma samples were obtained simultaneously from a total of 100 subjects. OF samples were analysed by OF screening test based on immunochromatography. The OF screening test cut-off values were 50 ng/mL for amphetamines (d-amphetamine) and methamphetamine/MDMA (d-methamphetamine), 30 ng/mL for cocaine (benzoylecgonine), 40 ng/mL for opiates (morphine), 20 ng/mL for benzodiazepines (nordazepam), and 25 ng/mL for cannabis (Δ9-tetrahydrocannabinol). LC-MS/MS method validation was performed according to the CLSI C62-A recommendations with the following parameters: matrix effect, lower limit of quantification (LLOQ), linearity, intra-day and inter-day precision and accuracy. The overall specificity, accuracy and negative predictive values (NPV) were acceptable and met the DRUID standard of >80%. The OF screening test device showed good sensitivity for cocaine, amphetamines and opiates, whereas it indicated poor sensitivity for methamphetamine/MDMA (66.7%) and failed to detect cannabis and benzodiazepines. The present study is the first report to evaluate the Kite Biotechnology OF screening test device. The diagnostic performance of the OF screening test device was acceptable for opiates, cocaine and amphetamines, but it was insufficient for methamphetamine/MDMA, benzodiazepines and cannabis because of sensitivity issues.
doi_str_mv 10.1016/j.clinbiochem.2021.04.009
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2516842472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009912021001120</els_id><sourcerecordid>2516842472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-c2715de20722ccd68a88a081656187d8c383a58148dbc2be129a2909e22daee43</originalsourceid><addsrcrecordid>eNqNkE2P2yAQhlG1q2427V-o2Nte7MLg2PhYRftRKVIv3TPCME6IbJMCzqr_vmSTVj3uBQQ87wzzEHLHWckZr7_uSzO4qXPe7HAsgQEvWVUy1n4gCy4bUUArxBVZsHxVtBzYDbmNcZ-PUMn6I7kRQkoAKRbk9eGoh1kn5yfqe5p2SK3T28nH5Aw9YOh9GPVk8PSqMxP0QPthdpZGExAnN21pwpioxaPLWOZpnLuY3kK6m2NeE01B932uaPyUgh_iJ3Ld6yHi58u-JC-PDz_Xz8Xmx9P39bdNYUTTpMJAw1cWgTUAxthaaik1k7xe1XlQK42QQq8kr6TtDHTIodXQshYBrEasxJLcn-segv8153-q0UWDw6An9HNUsOK1rKBqIKPtGTXBxxiwV4fgRh1-K87Uybvaq_-8q5N3xSqVJefsl0ubuRvR_kv-FZ2B9RnAPOzRYVDROMyKrAtokrLevaPNH3mfm6c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2516842472</pqid></control><display><type>article</type><title>Evaluation of the diagnostic performance of an oral fluid screening test device for substance abuse at traffic controls</title><source>ScienceDirect Freedom Collection</source><creator>Avcioglu, Gamze ; Yilmaz, Gulsen ; Yalcin Sahiner, Safak ; Kozaci, L. Didem ; Bal, Ceylan ; Yilmaz, Fatma Meric</creator><creatorcontrib>Avcioglu, Gamze ; Yilmaz, Gulsen ; Yalcin Sahiner, Safak ; Kozaci, L. Didem ; Bal, Ceylan ; Yilmaz, Fatma Meric</creatorcontrib><description>The aim of this study was to evaluate the analytical performance of the Kite Biotechnology Oral fluid (OF) screening test device, which is used for roadside screening of cannabis, opiates, amphetamines, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), cocaine and benzodiazepines by comparing samples with matched plasma samples, analysed via liquid chromatography–tandem mass spectrometry (LC-MS/MS) for confirmation. OF and plasma samples were obtained simultaneously from a total of 100 subjects. OF samples were analysed by OF screening test based on immunochromatography. The OF screening test cut-off values were 50 ng/mL for amphetamines (d-amphetamine) and methamphetamine/MDMA (d-methamphetamine), 30 ng/mL for cocaine (benzoylecgonine), 40 ng/mL for opiates (morphine), 20 ng/mL for benzodiazepines (nordazepam), and 25 ng/mL for cannabis (Δ9-tetrahydrocannabinol). LC-MS/MS method validation was performed according to the CLSI C62-A recommendations with the following parameters: matrix effect, lower limit of quantification (LLOQ), linearity, intra-day and inter-day precision and accuracy. The overall specificity, accuracy and negative predictive values (NPV) were acceptable and met the DRUID standard of &gt;80%. The OF screening test device showed good sensitivity for cocaine, amphetamines and opiates, whereas it indicated poor sensitivity for methamphetamine/MDMA (66.7%) and failed to detect cannabis and benzodiazepines. The present study is the first report to evaluate the Kite Biotechnology OF screening test device. The diagnostic performance of the OF screening test device was acceptable for opiates, cocaine and amphetamines, but it was insufficient for methamphetamine/MDMA, benzodiazepines and cannabis because of sensitivity issues.</description><identifier>ISSN: 0009-9120</identifier><identifier>EISSN: 1873-2933</identifier><identifier>DOI: 10.1016/j.clinbiochem.2021.04.009</identifier><identifier>PMID: 33882283</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cut-off ; LC-MS/MS ; Oral fluid ; Oral fluid screening test device ; Plasma ; Substance abuse</subject><ispartof>Clinical biochemistry, 2021-07, Vol.93, p.112-118</ispartof><rights>2021 The Canadian Society of Clinical Chemists</rights><rights>Copyright © 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-c2715de20722ccd68a88a081656187d8c383a58148dbc2be129a2909e22daee43</citedby><cites>FETCH-LOGICAL-c377t-c2715de20722ccd68a88a081656187d8c383a58148dbc2be129a2909e22daee43</cites><orcidid>0000-0002-3080-5964</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33882283$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Avcioglu, Gamze</creatorcontrib><creatorcontrib>Yilmaz, Gulsen</creatorcontrib><creatorcontrib>Yalcin Sahiner, Safak</creatorcontrib><creatorcontrib>Kozaci, L. Didem</creatorcontrib><creatorcontrib>Bal, Ceylan</creatorcontrib><creatorcontrib>Yilmaz, Fatma Meric</creatorcontrib><title>Evaluation of the diagnostic performance of an oral fluid screening test device for substance abuse at traffic controls</title><title>Clinical biochemistry</title><addtitle>Clin Biochem</addtitle><description>The aim of this study was to evaluate the analytical performance of the Kite Biotechnology Oral fluid (OF) screening test device, which is used for roadside screening of cannabis, opiates, amphetamines, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), cocaine and benzodiazepines by comparing samples with matched plasma samples, analysed via liquid chromatography–tandem mass spectrometry (LC-MS/MS) for confirmation. OF and plasma samples were obtained simultaneously from a total of 100 subjects. OF samples were analysed by OF screening test based on immunochromatography. The OF screening test cut-off values were 50 ng/mL for amphetamines (d-amphetamine) and methamphetamine/MDMA (d-methamphetamine), 30 ng/mL for cocaine (benzoylecgonine), 40 ng/mL for opiates (morphine), 20 ng/mL for benzodiazepines (nordazepam), and 25 ng/mL for cannabis (Δ9-tetrahydrocannabinol). LC-MS/MS method validation was performed according to the CLSI C62-A recommendations with the following parameters: matrix effect, lower limit of quantification (LLOQ), linearity, intra-day and inter-day precision and accuracy. The overall specificity, accuracy and negative predictive values (NPV) were acceptable and met the DRUID standard of &gt;80%. The OF screening test device showed good sensitivity for cocaine, amphetamines and opiates, whereas it indicated poor sensitivity for methamphetamine/MDMA (66.7%) and failed to detect cannabis and benzodiazepines. The present study is the first report to evaluate the Kite Biotechnology OF screening test device. The diagnostic performance of the OF screening test device was acceptable for opiates, cocaine and amphetamines, but it was insufficient for methamphetamine/MDMA, benzodiazepines and cannabis because of sensitivity issues.</description><subject>Cut-off</subject><subject>LC-MS/MS</subject><subject>Oral fluid</subject><subject>Oral fluid screening test device</subject><subject>Plasma</subject><subject>Substance abuse</subject><issn>0009-9120</issn><issn>1873-2933</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkE2P2yAQhlG1q2427V-o2Nte7MLg2PhYRftRKVIv3TPCME6IbJMCzqr_vmSTVj3uBQQ87wzzEHLHWckZr7_uSzO4qXPe7HAsgQEvWVUy1n4gCy4bUUArxBVZsHxVtBzYDbmNcZ-PUMn6I7kRQkoAKRbk9eGoh1kn5yfqe5p2SK3T28nH5Aw9YOh9GPVk8PSqMxP0QPthdpZGExAnN21pwpioxaPLWOZpnLuY3kK6m2NeE01B932uaPyUgh_iJ3Ld6yHi58u-JC-PDz_Xz8Xmx9P39bdNYUTTpMJAw1cWgTUAxthaaik1k7xe1XlQK42QQq8kr6TtDHTIodXQshYBrEasxJLcn-segv8153-q0UWDw6An9HNUsOK1rKBqIKPtGTXBxxiwV4fgRh1-K87Uybvaq_-8q5N3xSqVJefsl0ubuRvR_kv-FZ2B9RnAPOzRYVDROMyKrAtokrLevaPNH3mfm6c</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Avcioglu, Gamze</creator><creator>Yilmaz, Gulsen</creator><creator>Yalcin Sahiner, Safak</creator><creator>Kozaci, L. Didem</creator><creator>Bal, Ceylan</creator><creator>Yilmaz, Fatma Meric</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3080-5964</orcidid></search><sort><creationdate>20210701</creationdate><title>Evaluation of the diagnostic performance of an oral fluid screening test device for substance abuse at traffic controls</title><author>Avcioglu, Gamze ; Yilmaz, Gulsen ; Yalcin Sahiner, Safak ; Kozaci, L. Didem ; Bal, Ceylan ; Yilmaz, Fatma Meric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-c2715de20722ccd68a88a081656187d8c383a58148dbc2be129a2909e22daee43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cut-off</topic><topic>LC-MS/MS</topic><topic>Oral fluid</topic><topic>Oral fluid screening test device</topic><topic>Plasma</topic><topic>Substance abuse</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Avcioglu, Gamze</creatorcontrib><creatorcontrib>Yilmaz, Gulsen</creatorcontrib><creatorcontrib>Yalcin Sahiner, Safak</creatorcontrib><creatorcontrib>Kozaci, L. Didem</creatorcontrib><creatorcontrib>Bal, Ceylan</creatorcontrib><creatorcontrib>Yilmaz, Fatma Meric</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Avcioglu, Gamze</au><au>Yilmaz, Gulsen</au><au>Yalcin Sahiner, Safak</au><au>Kozaci, L. Didem</au><au>Bal, Ceylan</au><au>Yilmaz, Fatma Meric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the diagnostic performance of an oral fluid screening test device for substance abuse at traffic controls</atitle><jtitle>Clinical biochemistry</jtitle><addtitle>Clin Biochem</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>93</volume><spage>112</spage><epage>118</epage><pages>112-118</pages><issn>0009-9120</issn><eissn>1873-2933</eissn><abstract>The aim of this study was to evaluate the analytical performance of the Kite Biotechnology Oral fluid (OF) screening test device, which is used for roadside screening of cannabis, opiates, amphetamines, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), cocaine and benzodiazepines by comparing samples with matched plasma samples, analysed via liquid chromatography–tandem mass spectrometry (LC-MS/MS) for confirmation. OF and plasma samples were obtained simultaneously from a total of 100 subjects. OF samples were analysed by OF screening test based on immunochromatography. The OF screening test cut-off values were 50 ng/mL for amphetamines (d-amphetamine) and methamphetamine/MDMA (d-methamphetamine), 30 ng/mL for cocaine (benzoylecgonine), 40 ng/mL for opiates (morphine), 20 ng/mL for benzodiazepines (nordazepam), and 25 ng/mL for cannabis (Δ9-tetrahydrocannabinol). LC-MS/MS method validation was performed according to the CLSI C62-A recommendations with the following parameters: matrix effect, lower limit of quantification (LLOQ), linearity, intra-day and inter-day precision and accuracy. The overall specificity, accuracy and negative predictive values (NPV) were acceptable and met the DRUID standard of &gt;80%. The OF screening test device showed good sensitivity for cocaine, amphetamines and opiates, whereas it indicated poor sensitivity for methamphetamine/MDMA (66.7%) and failed to detect cannabis and benzodiazepines. The present study is the first report to evaluate the Kite Biotechnology OF screening test device. The diagnostic performance of the OF screening test device was acceptable for opiates, cocaine and amphetamines, but it was insufficient for methamphetamine/MDMA, benzodiazepines and cannabis because of sensitivity issues.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33882283</pmid><doi>10.1016/j.clinbiochem.2021.04.009</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3080-5964</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0009-9120
ispartof Clinical biochemistry, 2021-07, Vol.93, p.112-118
issn 0009-9120
1873-2933
language eng
recordid cdi_proquest_miscellaneous_2516842472
source ScienceDirect Freedom Collection
subjects Cut-off
LC-MS/MS
Oral fluid
Oral fluid screening test device
Plasma
Substance abuse
title Evaluation of the diagnostic performance of an oral fluid screening test device for substance abuse at traffic controls
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A11%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20diagnostic%20performance%20of%20an%20oral%20fluid%20screening%20test%20device%20for%20substance%20abuse%20at%20traffic%20controls&rft.jtitle=Clinical%20biochemistry&rft.au=Avcioglu,%20Gamze&rft.date=2021-07-01&rft.volume=93&rft.spage=112&rft.epage=118&rft.pages=112-118&rft.issn=0009-9120&rft.eissn=1873-2933&rft_id=info:doi/10.1016/j.clinbiochem.2021.04.009&rft_dat=%3Cproquest_cross%3E2516842472%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c377t-c2715de20722ccd68a88a081656187d8c383a58148dbc2be129a2909e22daee43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2516842472&rft_id=info:pmid/33882283&rfr_iscdi=true